Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 3
1991 5
1992 5
1993 6
1994 7
1995 7
1996 8
1997 5
1998 9
1999 11
2000 7
2001 8
2002 4
2003 8
2004 7
2005 7
2006 5
2007 9
2008 8
2009 13
2010 8
2011 5
2012 6
2013 12
2014 6
2015 9
2016 4
2017 9
2018 11
2019 2
2020 6
2021 3
2022 8
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, van Tellingen O, van de Ven M, Begthel H, Boj SF, Clevers H, Roodhart JML, Bos JL, Snippert HJG. Mertens S, et al. Among authors: van tellingen o. Cell Rep. 2023 Apr 25;42(4):112324. doi: 10.1016/j.celrep.2023.112324. Epub 2023 Mar 30. Cell Rep. 2023. PMID: 37000626 Free article.
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, Pak HS, Bleijerveld OB, Mordente K, Navarro JM, Blommaert N, Nielsen MM, Lovecchio D, Stone E, Georgiou G, de Gooijer MC, van Tellingen O, Altelaar M, Joosten RP, Perrakis A, Olweus J, Bassani-Sternberg M, Peeper DS, Agami R. Pataskar A, et al. Among authors: van tellingen o. Nature. 2022 Mar;603(7902):721-727. doi: 10.1038/s41586-022-04499-2. Epub 2022 Mar 9. Nature. 2022. PMID: 35264796 Free PMC article.
An Experimenter's Guide to Glioblastoma Invasion Pathways.
de Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T, van Tellingen O. de Gooijer MC, et al. Among authors: van tellingen o. Trends Mol Med. 2018 Sep;24(9):763-780. doi: 10.1016/j.molmed.2018.07.003. Epub 2018 Jul 30. Trends Mol Med. 2018. PMID: 30072121 Review.
BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis.
Uceda-Castro R, Margarido AS, Song JY, de Gooijer MC, Messal HA, Chambers CR, Nobis M, Çitirikkaya CH, Hahn K, Seinstra D, Herrmann D, Timpson P, Wesseling P, van Tellingen O, Vennin C, van Rheenen J. Uceda-Castro R, et al. Among authors: van tellingen o. Sci Adv. 2023 Oct 20;9(42):eabp9530. doi: 10.1126/sciadv.abp9530. Epub 2023 Oct 18. Sci Adv. 2023. PMID: 37851804 Free PMC article.
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Sparreboom A, et al. Among authors: van tellingen o. Anticancer Drugs. 1998 Jan;9(1):1-17. doi: 10.1097/00001813-199801000-00001. Anticancer Drugs. 1998. PMID: 9491787 Review.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mulero-Sánchez A, et al. Among authors: van tellingen o. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. Mol Oncol. 2023. PMID: 36650715 Free PMC article.
Strategies to target drugs to gliomas and CNS metastases of solid tumors.
Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. Milojkovic Kerklaan B, et al. Among authors: van tellingen o. J Neurol. 2016 Mar;263(3):428-40. doi: 10.1007/s00415-015-7919-9. Epub 2015 Oct 17. J Neurol. 2016. PMID: 26477024 Review.
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.
Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, Kuiken HJ, Morris B, Edwards F, Jochems F, van Tellingen O, Boeije M, Proost N, Jansen RA, Qin S, Jin H, Koen van der Mijn JC, Schepers A, Venkatesan S, Qin W, Beijersbergen RL, Wang L, Bernards R. Chen M, et al. Among authors: van tellingen o. Cell Rep Med. 2024 Mar 19;5(3):101471. doi: 10.1016/j.xcrm.2024.101471. Cell Rep Med. 2024. PMID: 38508142 Free PMC article.
222 results